• Phase


  • Contact person

    Tomas Eriksson, CEO

  • Email


  • Area

    Pharma & Biotech


Sinntaxis AB is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke. Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.

Tomas Eriksson has more than 10 years’ experience as CEO and co-founder of A1M Pharma, and 20+ years of experience in international marketing and sales, primarily within medical technology and diagnostics. He has also been involved in a number of early stage projects in life science, with a focus on business development and financing.

Did you know?

The Sinntaxis approach has shown improved restoration of brain function, enhancing the speed and extent of recovery after stroke.

© 2022 Copyright SmiLe Incubator